Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta(2) agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). This 12-wee...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Pulm Med
Glavni autori: Singh, Dave, Worsley, Sally, Zhu, Chang-Qing, Hardaker, Liz, Church, Alison
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545560/
https://ncbi.nlm.nih.gov/pubmed/26286141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-015-0092-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items